Ventus Therapeutics Inc.

Zydus Lifesciences Limited has been expanding the number of indications for which its novel molecules are being studied as it follows the "pipeline-in-a-drug" model successfully implemented by others

Efforts to unlock the potential of the NLRP3 inhibitor drugs and treat the so-called inflammasome has been ongoing for decades, but a new burst of investment could finally see the field deliver. One c

After years of slow progress, companies working in the field of NLRP3 inflammasome inhibitors are hoping to soon finally realize the promise of the novel drug class. The NLRP3 inflammasome is a multi-

Having played such a crucial role for nearly three years in addressing the global COVID-19 pandemic, the pharma and biotech sectors are enjoying a return to something approaching normality. Neverthele